Evaluation of the Potential of the MicroRNAs to Predict Chemotherapy Resistance in Breast Cancer Patients: A Systemic Review with Meta-analysis

Document Type : Review Article


1 Department of Pharmacology and Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Department of Internal Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

4 Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran


Background and aim: Breast cancer is the most common cancer diagnosed in women. In predicting the survival rate of breast cancer patients, factors such as age, race, spread of the disease, stage of diagnosis, and involvement of lymph nodes are involved. In this study, the potential of the microRNAs to predict chemotherapy resistance in breast cancer patients has been investigated.
Material and methods: In the present systematic review and meta-analysis, information about microRNAs to predict chemotherapy resistance in breast cancer patients in all articles published until the end of May 2023 through searching in databases PubMed, Scopus, Science Direct, ISI, Web of Knowledge, Elsevier, Wiley, and Embase and Google Scholar search engine were extracted using keywords and their combinations by two trained researchers independently. Data analysis was done using the fixed effects model in the meta-analysis by STATA (version 17); a p-value less than 0.05 was considered significant.
Results: Eight studies with a sample size of 509 breast cancer patients were included in the meta-analysis. The chemotherapeutic response of miRNAs in breast cancer patients receiving chemotherapy was 0.56 (ES, 95% CI: -1.30, 2.42; 0.03. I2 =0(p=1.00)).
Conclusions: The meta-analysis of the present study shows that there is a statistical relationship between predicting chemotherapy resistance and miRNA expression in breast cancer patients.


Main Subjects

[1] Afifi AM, Saad AM, Al‐Husseini MJ, Elmehrath AO, Northfelt DW, Sonbol MB. Causes of death after breast cancer diagnosis: A US population‐based analysis. Cancer. 2020;126(7):1559-67. https://doi.org/10.1002/cncr.32648.
[2] Zaidi Z, Cherif MH. The worldwide female breast cancer incidence and survival, 2018. Pan Arab Journal of Oncology. 2019;12(2):46.
[3] Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast. 2022;66:15-23. https://doi.org/10.1016/j.breast.2022.08.010.
[4] He L, Wick N, Germans SK, Peng Y. The role of breast cancer stem cells in chemoresistance and metastasis in triple-negative breast cancer. Cancers. 2021;13(24):6209. https://doi.org/10.3390/cancers13246209.
[5] Waks AG, Winer EP. Breast cancer treatment: a review. Jama. 2019;321(3):288-300. https://doi.org/10.1001/jama.2018.19323.
[6] Effiong EB, Nweke BC, Okereke AH, Pius ANO. BREAST CANCER–REVIEW. Journal of Global Biosciences Vol. 2022;11(3):9248-57.
[7] Germani MM, Borelli B, Boraschi P, Antoniotti C, Ugolini C, Urbani L, et al. The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features. Cancer Treatment Reviews. 2022;106:102382. https://doi.org/10.1016/j.ctrv.2022.102382.
[8] Harries M, Taylor A, Holmberg L, Agbaje O, Garmo H, Kabilan S, et al. Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients. Cancer epidemiology. 2014;38(4):427-34. https://doi.org/10.1016/j.canep.2014.05.005.
[9] You JY, Park S, Lee ES. Brief Overview of Breast Cancer Treatment. A Practical Guide to Breast Cancer Treatment. 2023:147-71. https://doi.org/10.1007/978-981-19-9044-1_4.
[10] Wang J, Yang M, Li Y, Han B. The role of microRNAs in the chemoresistance of breast cancer. Drug development research. 2015;76(7):368-74. https://doi.org/10.1002/ddr.21275.
[11] Fan T, Kuang G, Long R, Han Y, Wang J. The overall process of metastasis: from initiation to a new tumor. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2022;1877(4):188750. https://doi.org/10.1016/j.bbcan.2022.188750.
[12] AL O, EX F, RIMENTAL P, ICAL BM, IEN S. Non-Coding RNAs and Cancer. Journal of Experimental and Basic Medical Sciences. 2021;2(2):211-7. https://doi.org/10.5606/jebms.2021.75659.
[13] Petri BJ, Klinge CM. Regulation of breast cancer metastasis signaling by miRNAs. Cancer and metastasis reviews. 2020;39:837-86. https://doi.org/10.1007/s10555-020-09905-7.
[14] Mollaei H, Safaralizadeh R, Rostami Z. MicroRNA replacement therapy in cancer. Journal of cellular physiology. 2019;234(8):12369-84. https://doi.org/10.1002/jcp.28058.
[15] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology. 2010;25:603-5. https://doi.org/10.1007/s10654-010-9491-z.
[16] Shao B, Wang X, Zhang L, Li D, Liu X, Song G, et al. Plasma microRNAs predict chemoresistance in patients with metastatic breast cancer. Technology in Cancer Research & Treatment. 2019;18:1533033819828709. https://doi.org/10.1177/1533033819828709.
[17] Yang Q, Zhao S, Shi Z, Cao L, Liu J, Pan T, et al. Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling. Journal of Experimental & Clinical Cancer Research. 2021;40(1):1-8.
[18] Salvador-Coloma C, Santaballa A, Sanmartín E, Calvo D, García A, Hervás D, et al. Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer. European Journal of Cancer. 2020;139:119-34. https://doi.org/10.1016/j.ejca.2020.08.020.
[19] Guo Q, Wen R, Shao B, Li Y, Jin X, Deng H, et al. Combined Let-7a and H19 signature: A prognostic index of progression-free survival in primary breast cancer patients. Journal of Breast Cancer. 2018;21(2):142-9. https://doi.org/10.4048/jbc.2018.21.2.142.
[20] Yu SJ, Yang L, Hong Q, Kuang XY, Di GH, Shao ZM. MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer. BMc cancer. 2018;18(1):1-11. https://doi.org/10.1186/s12885-017-3930-0.
[21] Raychaudhuri M, Bronger H, Buchner T, Kiechle M, Weichert W, Avril S. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer. Breast cancer research and treatment. 2017;162:511-21. https://doi.org/10.1007/s10549-017-4132-9.
[22] Sha LY, Zhang Y, Wang W, Sui X, Liu SK, Wang T, et al. MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer. European Review for Medical & Pharmacological Sciences. 2016;20(11):2201-08.
[23] Zhu Y, Wu J, Li S, Ma R, Cao H, Ji M, et al. The function role of miR-181a in chemosensitivity to adriamycin by targeting Bcl-2 in low-invasive breast cancer cells. Cellular physiology and biochemistry. 2013;32(5):1225-37. https://doi.org/10.1159/000354521.
[24] Zheng R, Pan L, Gao J, Ye X, Chen L, Zhang X, et al. Prognostic value of miR-106b expression in breast cancer patients. journal of surgical research. 2015;195(1):158-65. https://doi.org/10.1016/j.jss.2014.12.035.
[25] Wang B, Wang H, Yang Z. MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R. 2012. https://doi.org/10.1371/journal.pone.0047053.
[26] Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, Børresen-Dale AL, et al. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clinical cancer research. 2015;21(5):1207-14. https://doi.org/10.1158/1078-0432.CCR-14-2011.
[27] Li Q, Liu M, Ma F, Luo Y, Cai R, Wang L, et al. Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel. PLoS One. 2014;9(8):e104870. https://doi.org/10.1371/journal.pone.0104870.
[28] Yu SJ, Hu JY, Kuang XY, Luo JM, Hou YF, Di GH, et al. MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer. Clinical cancer research. 2013;19(6):1389-99. https://doi.org/10.1158/1078-0432.CCR-12-1959.
[29] Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M, et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clinical Cancer Research. 2012;18(21):5972-82. https://doi.org/10.1158/1078-0432.CCR-12-1407.
[30] Hong L, Yang J, Han Y, Lu Q, Cao J, Syed L. High expression of miR-210 predicts poor survival in patients with breast cancer: a meta-analysis. Gene. 2012;507(2):135-8. https://doi.org/10.1016/j.gene.2012.07.025.
[31] Berruti A, Amoroso V, Gallo F, Bertaglia V, Simoncini E, Pedersini R, et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. Journal of clinical oncology. 2014;32(34):3883-91. http://dx.doi.org/10.1200/JCO.2014.55.2836.
[32] Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet. 2014;384(9938):164-72. https://doi.org/10.1016/S0140-6736(13)62422-8.